CA2556758A1 - Use of beta-lapachone for treating or preventing cancer - Google Patents

Use of beta-lapachone for treating or preventing cancer Download PDF

Info

Publication number
CA2556758A1
CA2556758A1 CA002556758A CA2556758A CA2556758A1 CA 2556758 A1 CA2556758 A1 CA 2556758A1 CA 002556758 A CA002556758 A CA 002556758A CA 2556758 A CA2556758 A CA 2556758A CA 2556758 A1 CA2556758 A1 CA 2556758A1
Authority
CA
Canada
Prior art keywords
cancer
lapachone
cell
cells
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002556758A
Other languages
English (en)
French (fr)
Inventor
Chiang Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2005/005354 external-priority patent/WO2005082353A2/en
Publication of CA2556758A1 publication Critical patent/CA2556758A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002556758A 2004-02-20 2005-02-16 Use of beta-lapachone for treating or preventing cancer Abandoned CA2556758A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US54591604P 2004-02-20 2004-02-20
US54591704P 2004-02-20 2004-02-20
US54595004P 2004-02-20 2004-02-20
US54591504P 2004-02-20 2004-02-20
US54591404P 2004-02-20 2004-02-20
US60/545,917 2004-02-20
US60/545,914 2004-02-20
US60/545,916 2004-02-20
US60/545,915 2004-02-20
US60/545,950 2004-02-20
US10/846,980 2004-05-14
US10/846,980 US20050187288A1 (en) 2004-02-20 2004-05-14 Beta-lapachone and methods of treating cancer
PCT/US2005/005354 WO2005082353A2 (en) 2004-02-20 2005-02-16 Use of beta-lapachone for treating or preventing cancer

Publications (1)

Publication Number Publication Date
CA2556758A1 true CA2556758A1 (en) 2005-09-09

Family

ID=56290562

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002556758A Abandoned CA2556758A1 (en) 2004-02-20 2005-02-16 Use of beta-lapachone for treating or preventing cancer

Country Status (4)

Country Link
US (1) US20050187288A1 (https=)
EP (1) EP1727537A2 (https=)
JP (2) JP2007523187A (https=)
CA (1) CA2556758A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
KR101752697B1 (ko) * 2015-04-17 2017-07-03 (주)나디안바이오 나프토퀴논계 화합물을 유효성분으로 포함하는 췌장염 예방 및 치료용 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194767T1 (de) * 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
US5440056A (en) * 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
US5807888A (en) * 1995-12-13 1998-09-15 Xechem International, Inc. Preparation of brominated paclitaxel analogues and their use as effective antitumor agents
US5760072A (en) * 1995-12-29 1998-06-02 Pharmachemie B.V. Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
US5773461A (en) * 1996-06-06 1998-06-30 Bristol-Myers Squibb Company 7-deoxy-6-substituted paclitaxels
CA2245029A1 (en) * 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
DE60031268T2 (de) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston Verfahren und zusammansetzung zur behandlung von krebs
US20050192361A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of colon cancer
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
US20050197406A1 (en) * 1999-04-14 2005-09-08 Li Chiang J. Method of treatment of lung cancer
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
EP1387677A2 (en) * 2000-11-07 2004-02-11 Dana-Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers using beta lapachone
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
US7070797B2 (en) * 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
US6458974B1 (en) * 2001-01-25 2002-10-01 Cyclis Pharmaceuticals, Inc. Synthesis of β-lapachone and its intermediates
US6962944B2 (en) * 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6890950B2 (en) * 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
AU2003254029A1 (en) * 2002-07-17 2004-02-02 Arqule, Inc. Activated checkpoint therapy and methods of use thereof
TW200420515A (en) * 2002-07-23 2004-10-16 Ppg Ind Ohio Inc Glass fiber sizing compositions, sized glass fibers, and polyolefin composites
US20060142271A1 (en) * 2002-09-17 2006-06-29 Klaus Muller Novel lapacho compounds and methods of use thereof
BR0316296A (pt) * 2002-11-18 2005-12-13 Arqule Inc Compostos lapacone e seus métodos de uso
WO2004050033A2 (en) * 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers
EP2033638A2 (en) * 2004-02-20 2009-03-11 Arqule, Inc. Beta-lapachone for the treatment of pancreatic cancer
JP2007523190A (ja) * 2004-02-20 2007-08-16 アークル・インコーポレーテツド 肺癌の治療のためのβ−ラパコンの使用
EP1722776A2 (en) * 2004-02-20 2006-11-22 Arqule, Inc. Use of beta-lapachone as a broad spectrum anti-cancer agent
WO2005082357A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating hematologic tumors
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
EP2033639A2 (en) * 2004-02-20 2009-03-11 Arqule, Inc. Beta-lapachone for the treatment of colon cancer
CA2556759A1 (en) * 2004-02-23 2005-09-09 Arqule, Inc. Beta-lapachone and s-phase drug combinations for cancer treatment
EP1877097B1 (en) * 2004-08-11 2012-06-20 Arqule, Inc. Aminoacid conjugates of beta-lapachone for tumor targeting

Also Published As

Publication number Publication date
JP2007523187A (ja) 2007-08-16
US20050187288A1 (en) 2005-08-25
EP1727537A2 (en) 2006-12-06
JP2008169220A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
AU2004226889B2 (en) Combination compositions of camptothecins and fluoropyrimidines
ES2424476T3 (es) Nanopartículas cargadas con fármaco antitumoral quimioterápico
Emerson et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan
AU2927999A (en) Use of epothilones for the treatment of cancer
US11116726B2 (en) Echinomycin formulation, method of making and method of use thereof
KR20180116298A (ko) 화학요법 유도 심장독성에 대응하기 위한 약제학적 조성물 및 방법
JP2018513130A (ja) Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用
CN115884768A (zh) 用于预防和治疗听力损失的方法
MXPA05006069A (es) Metodos para inhibir cancer y formacion de cicatrices.
JP2008169220A (ja) 癌を処置または予防するためのβ−ラパコンの使用
WO2005082353A2 (en) Use of beta-lapachone for treating or preventing cancer
EP1313459B1 (en) Polycyclic dianthraquinones as anti-cancer and anti-angiogenic agents
CN110381937A (zh) Mcl-1抑制剂和紫杉烷化合物的组合及其用途和药物组合物
KR102958185B1 (ko) 암 치료용 글리시리진-분지형 폴리에틸렌글리콜 컨쥬게이트
US10639372B2 (en) Nucleic acid, medical nanoparticle, and pharmaceutical composition thereof
EP2033640A2 (en) Beta-lapachone for the treatment of lung cancer
US20240398843A1 (en) Glycyrrhizin-branched polyethylene glycol conjugate for treating cancer
TWI434829B (zh) 以密環菌乙素來治療癌症之新穎用途
WO2004078168A1 (en) A composition comprising phytosphingosine or a derivative thereof
EP2033638A2 (en) Beta-lapachone for the treatment of pancreatic cancer
WO2023133086A1 (en) Incomplete autophagy induction for the treatment of cancer
TWI406658B (zh) 使用異硫氰酸酯類來治療癌症之方法及用途
HK40089168A (zh) 用於预防和治疗听力损失的方法
SC et al. Antitumor Efficacy, Pharmacokinetics, and Biodistribution of NX 211: A Low-Clearance Liposomal Formulation of Lurtotecan
Peloso et al. Opioids in non-cancer pain: Once-daily controlled-release tramadol and sustained-release diclofenac relieves chronic pain due to osteoarthritis: a randomized controlled trial

Legal Events

Date Code Title Description
FZDE Discontinued